NEW YORK, May 4 (Reuters) - The enormous demand for
weight-loss treatments like Novo Nordisk's Wegovy
could support as many as 10 competing products with annual sales
reaching up to $100 billion within a decade. | 12:42pm
NEW YORK (Reuters) - The enormous demand for weight-loss treatments like Novo Nordisk's Wegovy could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said. More than half a dozen companies, from Pfizer Inc and Amgen Inc to smaller players like Altimmune Inc, are working on weight-loss therapies similar to Wegovy, viewing them as important future growth drivers. Novo was first to introduce an effective treatment shown to help people lose up to 15% of their weight. Eli Lilly and Co is expected to receive a U.S. weight loss approval for its similar drug, Mounjaro, later this year. | 06:22am
Wegovy an under-the-skin injection that showed promise in weight-loss clinical trials is the first drug approved for chronic weight management since 2014.